1. PRODUCT AND COMPANY IDENTIFICATION

Product name: Ivermectin Liquid Formulation

Manufacturer or supplier’s details
Company: MSD
Address: 50 Tuas West Drive
          Singapore - Singapore 638408
Telephone: +1-908-740-4000
Emergency telephone number: 65 6697 2111 (24/7/365)
E-mail address: EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use
Recommended use: Veterinary product

2. HAZARDS IDENTIFICATION

GHS Classification
Skin corrosion/irritation: Category 2
Serious eye damage/eye irritation: Category 2
Reproductive toxicity: Category 1B
Specific target organ toxicity - single exposure (Oral): Category 2 (Central nervous system)
Specific target organ toxicity - single exposure: Category 3
Specific target organ toxicity - repeated exposure (Oral): Category 2 (Central nervous system)
Short-term (acute) aquatic hazard: Category 1
Long-term (chronic) aquatic hazard: Category 1

GHS label elements
Hazard pictograms: [Image]
Signal word: Danger
SAFETY DATA SHEET

Ivermectin Liquid Formulation

Hazard statements:
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
H360D May damage the unborn child.
H371 May cause damage to organs (Central nervous system) if swallowed.
H373 May cause damage to organs (Central nervous system) through prolonged or repeated exposure if swallowed.
H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements:
Prevention:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe mist or vapours.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P271 Use only outdoors or in a well-ventilated area.
P273 Avoid release to the environment.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.
Response:
P302 + P352 IF ON SKIN: Wash with plenty of water.
P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/ doctor if you feel unwell.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P308 + P311 IF exposed or concerned: Call a POISON CENTER/ doctor.
P332 + P313 If skin irritation occurs: Get medical advice/ attention.
P337 + P313 If eye irritation persists: Get medical advice/ attention.
P391 Collect spillage.
Storage:
P405 Store locked up.
Disposal:
P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification
None known.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture
Components
4. FIRST AID MEASURES

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled: If inhaled, remove to fresh air. Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person.

Most important symptoms and effects, both acute and delayed: Causes skin irritation. Causes serious eye irritation. May cause respiratory irritation. May damage the unborn child. May cause damage to organs if swallowed. May cause damage to organs through prolonged or repeated exposure if swallowed.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician: Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

Specific hazards during firefighting: Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides
Nitrogen oxides (NOx)

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

Special protective equipment for firefighters:
- In the event of fire, wear self-contained breathing apparatus.
- Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures:
  - Use personal protective equipment.
  - Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

- Environmental precautions:
  - Avoid release to the environment.
  - Prevent further leakage or spillage if safe to do so.
  - Prevent spreading over a wide area (e.g. by containment or oil barriers).
  - Retain and dispose of contaminated wash water.
  - Local authorities should be advised if significant spillages cannot be contained.

- Methods and materials for containment and cleaning up:
  - Soak up with inert absorbent material.
  - For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
  - Clean up remaining materials from spill with suitable absorbent.
  - Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
  - Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

- Technical measures:
  - See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

- Local/Total ventilation:
  - If sufficient ventilation is unavailable, use with local exhaust ventilation.

- Advice on safe handling:
  - Do not get on skin or clothing.
  - Do not breathe mist or vapours.
  - Do not swallow.
  - Do not get in eyes.
  - Wash skin thoroughly after handling.
  - Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
  - Keep container tightly closed.
  - Already sensitised individuals should consult their physician regarding working with respiratory irritants or sensitisers.
  - Do not eat, drink or smoke when using this product.
  - Take care to prevent spills, waste and minimize release to the environment.
Conditions for safe storage: Keep in properly labelled containers. Store locked up. Keep tightly closed. Keep in a cool, well-ventilated place. Store in accordance with the particular national regulations.

Materials to avoid: Do not store with the following product types: Strong oxidizing agents

### 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Components with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ivermectin</td>
<td>70288-86-7</td>
<td>TWA</td>
<td>0.05 mg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Further information: Skin</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>0.5 mg/100 cm²</td>
</tr>
</tbody>
</table>

#### Biological occupational exposure limits

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Control parameters</th>
<th>Biological specimen</th>
<th>Sampling time</th>
<th>Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>N-Methyl-2-pyrrolidone</td>
<td>872-50-4</td>
<td>5-Hydroxy-N-methyl-2-pyrrolidone</td>
<td>Urine</td>
<td>End of shift (As soon as possible after exposure ceases)</td>
<td>100 mg/l</td>
<td>ACGIH BEI</td>
</tr>
</tbody>
</table>

#### Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., dripless quick connections). All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

#### Personal protective equipment

**Respiratory protection**: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

**Filter type**: Combined particulates and organic vapour type

**Hand protection**: Chemical-resistant gloves

**Remarks**: Consider double gloving.
SAFETY DATA SHEET

Ivermectin Liquid Formulation

Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : liquid
Colour : light yellow
Odour : characteristic
Odour Threshold : No data available
pH : Not applicable
Melting point/freezing point : No data available
Initial boiling point and boiling range : No data available
Flash point : > 100 °C
Evaporation rate : No data available
Flammability (solid, gas) : Not applicable
Flammability (liquids) : Not applicable
Upper explosion limit / Upper flammability limit : No data available
Lower explosion limit / Lower flammability limit : No data available
10. STABILITY AND REACTIVITY

Reactivity: Not classified as a reactivity hazard.
Chemical stability: Stable under normal conditions.
Possibility of hazardous reactions: Can react with strong oxidizing agents.
Conditions to avoid: None known.
Incompatible materials: Oxidizing agents
Hazardous decomposition products: No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure:
- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity
Not classified based on available information.

Product:
- Acute oral toxicity: Acute toxicity estimate: > 2,000 mg/kg
  Method: Calculation method
- Acute dermal toxicity: Acute toxicity estimate: > 2,000 mg/kg
  Method: Calculation method
SAFETY DATA SHEET

Ivermectin Liquid Formulation

Components:

N-Methyl-2-pyrrolidone:
Acute oral toxicity   :  LD50 (Rat): 4,150 mg/kg
Acute inhalation toxicity :  LC50 (Rat): > 5.1 mg/l
                      :     Exposure time: 4 h
                      :     Test atmosphere: dust/mist
                      :     Method: OECD Test Guideline 403
Acute dermal toxicity :  LD50 (Rat): > 5,000 mg/kg

Ivermectin:
Acute oral toxicity   :  LD50 (Rat): 50 mg/kg
                      :     LD50 (Mouse): 25 mg/kg
                      :     LD50 (Monkey): > 24 mg/kg
                      :     Target Organs: Central nervous system
                      :     Symptoms: Vomiting, Dilatation of the pupil
                      :     Remarks: No mortality observed at this dose.
Acute inhalation toxicity :  LC50 (Rat): 5.11 mg/l
                      :     Exposure time: 1 h
                      :     Test atmosphere: dust/mist
Acute dermal toxicity :  LD50 (Rabbit): 406 mg/kg
                      :     LD50 (Rat): > 660 mg/kg

Skin corrosion/irritation
Causes skin irritation.

Components:

N-Methyl-2-pyrrolidone:
Result :  Skin irritation

Ivermectin:
Species :  Rabbit
Result :  No skin irritation

Serious eye damage/eye irritation
Causes serious eye irritation.

Components:

N-Methyl-2-pyrrolidone:
Species :  Rabbit
Result :  Irritation to eyes, reversing within 21 days
Ivermectin Liquid Formulation

Ivermectin:
Species: Rabbit
Result: Mild eye irritation

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Components:

N-Methyl-2-pyrrolidone:
Test Type: Local lymph node assay (LLNA)
Exposure routes: Skin contact
Species: Mouse
Method: OECD Test Guideline 429
Result: negative
Remarks: Based on data from similar materials

Ivermectin:
Exposure routes: Dermal
Species: Humans
Result: Does not cause skin sensitisation.

Germ cell mutagenicity
Not classified based on available information.

Components:

N-Methyl-2-pyrrolidone:
Genotoxicity in vitro:
Test Type: Bacterial reverse mutation assay (AMES)
Method: OECD Test Guideline 471
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Method: OECD Test Guideline 476
Result: negative

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Result: negative

Genotoxicity in vivo:
Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Method: OECD Test Guideline 474
Result: negative

Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Hamster
Application Route: Ingestion
Method: OECD Test Guideline 475
Result: negative

Ivermectin:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Test system: human diploid fibroblasts
Result: negative

Test Type: Mouse Lymphoma
Result: negative

Carcinogenicity
Not classified based on available information.

Components:

N-Methyl-2-pyrrolidone:
Species: Rat
Application Route: Ingestion
Exposure time: 2 Years
Result: negative

Species: Rat
Application Route: inhalation (vapour)
Exposure time: 2 Years
Result: negative

Ivermectin:
Species: Rat
Application Route: Oral
NOAEL: 1.5 mg/kg body weight
Result: negative
Remarks: Based on data from similar materials

Species: Mouse
Application Route: Oral
NOAEL: 2.0 mg/kg body weight
Result: negative
Remarks: Based on data from similar materials

Reproductive toxicity
May damage the unborn child.

Components:

N-Methyl-2-pyrrolidone:
Effects on fertility: Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 416
Result: negative

Effects on foetal development:

Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 414
Result: positive

Test Type: Fertility/early embryonic development
Species: Rat
Application Route: inhalation (vapour)
Result: positive

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Ingestion
Result: positive

Reproductive toxicity - Assessment:

Clear evidence of adverse effects on development, based on animal experiments.

Ivermectin:

Effects on fertility:

Test Type: Fertility
Species: Rat
Application Route: Oral
Fertility: NOAEL: 0.6 mg/kg body weight
Result: Animal testing did not show any effects on fertility.

Effects on foetal development:

Test Type: Development
Species: Mouse
Application Route: Oral
Developmental Toxicity: NOAEL: 0.2 mg/kg body weight
Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 0.4 mg/kg body weight
Result: Embryotoxic effects and adverse effects on the offspring were detected.
Remarks: The mechanism or mode of action may not be relevant in humans.

Test Type: Development
Species: Rabbit
Application Route: Oral
Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses
STOT - single exposure
May cause respiratory irritation.
May cause damage to organs (Central nervous system) if swallowed.

Components:

N-Methyl-2-pyrrolidone:
Assessment : May cause respiratory irritation.

Ivermectin:
Target Organs : Central nervous system
Assessment : Causes damage to organs.

STOT - repeated exposure
May cause damage to organs (Central nervous system) through prolonged or repeated exposure if swallowed.

Components:

Ivermectin:
Target Organs : Central nervous system
Assessment : Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity
Components:

N-Methyl-2-pyrrolidone:
Species : Rat, male
NOAEL : 169 mg/kg
LOAEL : 433 mg/kg
Application Route : Ingestion
Exposure time : 90 Days
Method : OECD Test Guideline 408

Species : Rat
NOAEL : 0.5 mg/l
LOAEL : 1 mg/l
Application Route : inhalation (dust/mist/fume)
Exposure time : 96 Days
Method : OECD Test Guideline 413

Species : Rabbit
NOAEL : 826 mg/kg
LOAEL : 1,653 mg/kg
Application Route : Skin contact
Exposure time : 20 Days

Ivermectin:
Species : Dog
NOAEL : 0.5 mg/kg
SAFETY DATA SHEET

Ivermectin Liquid Formulation

<table>
<thead>
<tr>
<th>LOAEL</th>
<th>1 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>14 Weeks</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Central nervous system</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Dilatation of the pupil, Tremors, Lack of coordination, anorexia</td>
</tr>
</tbody>
</table>

Species: Monkey
NOAEL: 1.2 mg/kg
Application Route: Oral
Exposure time: 2 Weeks
Remarks: No significant adverse effects were reported

Species: Rat
NOAEL: 0.4 mg/kg
LOAEL: 0.8 mg/kg
Application Route: Oral
Exposure time: 3 Months
Target Organs: spleen, Bone marrow, Kidney
Remarks: No significant adverse effects were reported

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

N-Methyl-2-pyrrolidone:
- Skin contact: Symptoms: Skin irritation

Ivermectin:
- Skin contact: Remarks: Can be absorbed through skin.
- Eye contact: Remarks: May irritate eyes.
- Ingestion: Symptoms: Drowsiness, Dilatation of the pupil, Tremors, Vomiting, anorexia, Lack of coordination

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

N-Methyl-2-pyrrolidone:
- Toxicity to fish: LC50 (Oncorhynchus mykiss (rainbow trout)): > 500 mg/l
  Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): > 1,000 mg/l
  Exposure time: 24 h
  Method: DIN 38412

Toxicity to algae/aquatic plants: ErC50 (Desmodesmus subspicatus (green algae)): 600.5 mg/l
  Exposure time: 72 h
  EC10 (Desmodesmus subspicatus (green algae)): 92.6 mg/l
  Exposure time: 72 h
## Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)

<table>
<thead>
<tr>
<th>Component</th>
<th>NOEC (Daphnia magna (Water flea))</th>
<th>Exposure time</th>
<th>Method</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ivermectin</td>
<td>12.5 mg/l</td>
<td>21 d</td>
<td>OECD Test Guideline 211</td>
</tr>
</tbody>
</table>

## Toxicity to microorganisms

<table>
<thead>
<tr>
<th>Component</th>
<th>EC50</th>
<th>Exposure time</th>
<th>Method</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ivermectin</td>
<td>&gt; 600 mg/l</td>
<td>30 min</td>
<td>ISO 8192</td>
</tr>
</tbody>
</table>

## Ivermectin:

### Toxicity to fish

- LC50 (Oncorhynchus mykiss (rainbow trout)): 0.003 mg/l
  - Exposure time: 96 h
- LC50 (Lepomis macrochirus (Bluegill sunfish)): 0.0048 mg/l
  - Exposure time: 96 h

### Toxicity to daphnia and other aquatic invertebrates

<table>
<thead>
<tr>
<th>Component</th>
<th>EC50</th>
<th>Exposure time</th>
<th>Method</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ivermectin</td>
<td>0.000025 mg/l</td>
<td>48 h</td>
<td>OECD Test Guideline 201</td>
</tr>
</tbody>
</table>

### Toxicity to algae/aquatic plants

<table>
<thead>
<tr>
<th>Component</th>
<th>EC50 (Pseudokirchneriella subcapitata (green algae)):</th>
<th>Exposure time</th>
<th>Method</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ivermectin</td>
<td>&gt; 9.1 mg/l</td>
<td>72 h</td>
<td>OECD Test Guideline 201</td>
</tr>
</tbody>
</table>

### M-Factor (Acute aquatic toxicity)

- Ivermectin: 10,000

### M-Factor (Chronic aquatic toxicity)

- Ivermectin: 10,000

### Persistence and degradability

#### Components:

**N-Methyl-2-pyrrolidone:**

<table>
<thead>
<tr>
<th>Component</th>
<th>Biodegradability</th>
<th>Method</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biodegradability</td>
<td>Readily biodegradable</td>
<td>OECD Test Guideline 301C</td>
</tr>
<tr>
<td>Biodegradation</td>
<td>73 %</td>
<td></td>
</tr>
<tr>
<td>Exposure time</td>
<td>28 d</td>
<td></td>
</tr>
</tbody>
</table>

**Ivermectin:**

<table>
<thead>
<tr>
<th>Component</th>
<th>Biodegradability</th>
<th>Method</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biodegradability</td>
<td>Not readily biodegradable</td>
<td>OECD Test Guideline 301C</td>
</tr>
<tr>
<td>Biodegradation</td>
<td>50 %</td>
<td></td>
</tr>
<tr>
<td>Exposure time</td>
<td>240 d</td>
<td></td>
</tr>
</tbody>
</table>

### Bioaccumulative potential

#### Components:

**N-Methyl-2-pyrrolidone:**

<table>
<thead>
<tr>
<th>Component</th>
<th>Partition coefficient: n-</th>
<th>Log Pow</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>log Pow: -0.46</td>
<td></td>
</tr>
</tbody>
</table>
octanol/water Method: OECD Test Guideline 107

**Ivermectin:**

Bioaccumulation: Bioconcentration factor (BCF): 74

Partition coefficient: n-octanol/water: log Pow: 3.22

**Mobility in soil**

No data available

**Other adverse effects**

No data available

### 13. DISPOSAL CONSIDERATIONS

**Disposal methods**

Waste from residues: Dispose of in accordance with local regulations.

Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

### 14. TRANSPORT INFORMATION

**International Regulations**

**UNRTDG**

UN number: UN 3082

Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Ivermectin)

Class: 9

Packing group: III

Labels: 9

**IATA-DGR**

UN/ID No.: UN 3082

Proper shipping name: Environmentally hazardous substance, liquid, n.o.s. (Ivermectin)

Class: 9

Packing group: III

Labels: Miscellaneous

Packing instruction (cargo aircraft): 964

Packing instruction (passenger aircraft): 964

Environmentally hazardous: yes

**IMDG-Code**

UN number: UN 3082

Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Ivermectin)

Class: 9

Packing group: III
Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

Special precautions for user
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

Workplace Safety and Health Act and Workplace Safety and Health (General Provisions) Regulations: This product is subjected to the SDS, labelling, PEL and other requirements in the Act/Regulations.

Environmental Protection and Management Act and Environmental Protection and Management (Hazardous Substances) Regulations : Not applicable

Fire Safety (Petroleum and Flammable Materials) Regulations : Not applicable

The components of this product are reported in the following inventories:

AICS : not determined
DSL : not determined
IECSC : not determined

16. OTHER INFORMATION

Further information

Date format : dd.mm.yyyy

Full text of other abbreviations
ACGIH BEI : ACGIH - Biological Exposure Indices (BEI)
The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.